Point72 Hong Kong Ltd Makes New $715,000 Investment in LivaNova PLC (NASDAQ:LIVN)

Point72 Hong Kong Ltd acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 15,438 shares of the company’s stock, valued at approximately $715,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC grew its position in LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after purchasing an additional 1,441 shares in the last quarter. Vestcor Inc purchased a new position in LivaNova during the 4th quarter worth approximately $204,000. Optimize Financial Inc purchased a new position in LivaNova during the 4th quarter worth approximately $208,000. Finally, Corton Capital Inc. purchased a new position in LivaNova during the 4th quarter worth approximately $214,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Up 0.6%

LIVN stock opened at $43.82 on Friday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $63.57. The company has a fifty day simple moving average of $38.28 and a 200 day simple moving average of $44.96. The firm has a market cap of $2.39 billion, a PE ratio of 104.33 and a beta of 0.84.

Analyst Ratings Changes

LIVN has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of LivaNova in a report on Tuesday. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Stifel Nicolaus lowered their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. Finally, The Goldman Sachs Group lowered their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $59.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.